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Abstract
Background: In practical sleep medicine, therapists face the question of whether or not to
discontinue the ongoing use of hypnotics in patients, as well as the possible effects of
discontinuation. The aim of this study was to evaluate the effects of discontinuing third-generation
hypnotics on the results of cognitive-behavioural therapy (CBT) for primary insomnia in patients
after long-term abuse.
Methods: Twenty-eight outpatients were treated by CBT for 8 weeks. The treatment outcome
was estimated by means of differences among subjective clinical scales and polysomnography
variables assessed before and after the treatment period. The therapeutic effect in a subgroup of
15 patients who had previously received hypnotics and were successively withdrawn during weeks
2–6 was compared to the effect achieved in patients who had not used hypnotics before CBT.
Results: There were no significant differences in baseline subjective and objective sleep
characteristics between the hypnotic abusers and non-abusers. According to clinical scales and
most polysomnographic measures, CBT was highly effective in both groups of subjects; it produced
the greatest changes in total sleep time, REM sleep and sleep efficiency. Unexpectedly,
discontinuation of hypnotics, as a factor in the analysis, was followed by an additional improvement
of sleep efficiency and wake after sleep onset parameters.
Conclusion: Our study confirmed the efficacy of CBT in both hypnotic-abusing and non-abusing
patients with chronic insomnia. The results of this study suggest that tapered withdrawal of third-
generation hypnotics during CBT therapy for chronic insomnia could be associated with
improvement rather than worsening of sleep continuity.
Background
Many patients suffering from chronic insomnia are pre-
scribed various types of hypnotics, particularly if treated
by non-psychiatrists. Thus, there is an increasing group of
people in the common population who subscribe to
daily, and often long-term, use of hypnotics. In many
patients, insomnia continues despite increases in daily
hypnotic dose. As a result, specialists are confronted with
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concurrently abolishing hypnotic abuse. Some therapists
select hypnotics with lower risk of tolerance and depend-
ence. Among these drugs, third-generation hypnotics have
become increasingly popular [1-3]. However, it is com-
monly agreed that psychological and behavioural inter-
ventions represent the most effective treatment option for
the management of persistent insomnia, as reviewed by
Morin et al. [4]. Cognitive-behavioural therapy (CBT) is
the mainstay of nonpharmacologic treatments for insom-
nia, with efficacy that lasts beyond the duration of treat-
ment [5]. The therapist then must decide whether or not
to discontinue the administration of hypnotics during
CBT. Discontinuation can be particularly difficult in
patients of higher age [6]. Although the benzodiazepine-
type hypnotics are associated with a higher risk of abuse,
the discontinuation of drug intake seems to be facilitated
by CBT [7]. On the other hand, some authors may choose
to continue the administration of hypnotics in order to
facilitate the therapeutic effect of CBT [8-10].
Therefore, there is no commonly agreed method of treat-
ment for patients who seek CBT after several years of daily
use of hypnotics. The uncertainty particularly concerns
the long-term use of third-generation hypnotics with a
low risk of abuse. The intention of the present study was
to elucidate some of the questions that confront the ther-
apist. Thus, the aim was to contribute to the answers to the
following questions:
1. Does treatment outcome with CBT for insomnia vary
between subjects with respect to hypnotic abuse?
2. Do baseline sleep characteristics, including sleep conti-
nuity and sleep architecture differ significantly with
respect to the abuse of third-generation hypnotic thera-
pies?
3. What is the CBT treatment outcome for insomnia in
patients after discontinuation of long-term hypnotic med-
ication, compared with treatment outcome in patients
who have used no hypnotics at all?
To clarify these questions, two subgroups of patients who
had or had not abused third-generation hypnotics for a
long time before CBT for insomnia, were examined. In the
subgroup of patients who had abused hypnotics, medica-
tion was discontinued during the first part of the CBT
period. This investigation was not a comparative study,
and should be considered as a clinical case series that had
two primary factors of interest: 1) Group (hypnotic abus-
ers [n = 15] vs. subjects without hypnotic abuse [n = 13]),
and 2) Time (baseline vs. end of treatment). The effect of
CBT was estimated according to differences among clini-
cal scales and sleep indicators obtained by means of poly-




The study was based on 28 consecutive outpatients (19
females and 9 males) aged 25 to 74 years (mean 44.35
years, s.d. 13.87) who had been diagnosed with primary
insomnia (F 51.0) according to ICD-10 [11]. The mean
duration of the disorder was 4.75 years (s.d. 1.60).
Patients with psychotic disorder, bipolar disorder, major
depression, personality disorders, chronic alcoholism,
dementia or other organic brain disorders were not
included in the study. All patients were in good physical
health. According to the polysomnography examination
conducted as part of the study, no signs of sleep-disor-
dered breathing could be found in any of the patients.
Among the patients, 15 had used zolpidem for more then
one year in doses of 15–20 mg daily (n = 12), 30–40 mg
daily (n = 2), and 70 mg daily (n = 1). The patients did not
use any another drug (such as benzodiazepines) for at
least two months before beginning the study. The charac-
teristics of this subgroup ("hypnotic abusers"), compared
with the subgroup of patients without hypnotics abuse
("hypnotic non-abusers", n = 13) can be found in Table 1.
The Prague Psychiatric Centre Institutional Review Board
reviewed and approved this study, and written informed
consent to participate in the research was obtained from
all subjects. The study was carried out in accordance with
the latest version of the Declaration of Helsinki.
Clinical examination
The clinical examination consisted of a psychiatric inter-
view and physical examination supplemented with a
study of sleep quality. All patients kept sleep logs, starting
one week before the first polysomnograph. The sleep
interviews and the medical examination were conducted
by a physician board-certified in psychiatry and sleep
medicine. To characterize the insomnia more precisely
and to assess therapeutic outcomes, the Insomnia Severity
Index (ISI) [12] and Epworth Sleepiness Scale (ESS) [13]
were completed prior to and following CBT. The follow-
ing scales and inventories were also applied, both before
and after CBT: the Beck Depression Inventory (BDI)
[14,15], the Beck Anxiety Inventory (BAI) [16] and the
Hamilton Rating Scale for Anxiety (HAMD) [17]. Besides
that, we also completed our modified version of Clinical
Global Impression Severity scale (mCGI-S) ranged from 2
(not ill) to 14 (extremely severely ill), which summed
together a standard version of CGI [18] rated from 1 (nor-
mal, not at all ill) to 7 (among the most extremely ill
patients) and a separate scale (with the same range) that
evaluated solely clinical global impression of a severity of
sleep disturbance and sleep quality. The assessment of ourPage 2 of 7
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(mCGI-I), which evaluate patient's improvement or wors-
ening with the range from 2 (very much improved) to 14
(very much worse), was performed in similar way. Sepa-
rate baseline scores for each subgroup can be found in
Table 1.
Study design
This investigation was based on the comparison of data
obtained from patients who were hypnotic abusers, and
patients without abuse potential. The examination and
therapy were the same in both subgroups. The study
began with an initial one-week observation period during
which the patients were asked to fill in their sleep logs.
Afterwards, a polysomnographic examination ("adap-
tive") was done. On the following day, the subjective
scores were registered and another polysomnographic
examination ("baseline") was performed. CBT (see
below) was then applied over the next 8 weeks. Fifteen
hypnotics abusing patients were provided with a step-by-
step withdrawal schedule, with the goal of eliminating
abuse of third-generation hypnotics by the 2nd to 6th week
(mostly in the 4th week) of treatment. We used several
principles (according to [7]), including 1) setting goals, 2)
stabilization with use of a single type of third-generation
hypnotic, 3) reduction of the initial dose by roughly 25%
per week until the lowest available dose was reached, and
4) introduction of an increasing number of medication-
free nights. The initial plan was to decrease medication by
25% at week 1, by 50% at week 2, and by 100% at week
4. The day after the treatment period ended, subjective
scores were registered and a third polysomnographic
examination ("post-treatment") was conducted.
Polysomnographic recording
The polysomnography concerned electroencephalogram
(EEG) derived from 9 channels (F3-T3, T3-T5, T5-O1, F8-
T4, T4-T6, T6-O2, Fz-Cz, T3-Cz, and Cz-T4), electrocardi-
ogram (ECG), naso-oral airflow, chest movements, oxy-
gen saturation, electrooculogram (EOG), and
electromyogram (EMG) from the submandibular, tho-
racic, and anterior tibialis muscles. The time to switch the
light off was chosen by the patient. Recording was then
started and continued until spontaneous awakening in
the morning. The polysomnographic records were scored
"blind" by an expert according to Rechtschaffen and Kales'
criteria [19].
Psychotherapy
Psychotherapy consisted of 8 sessions (each lasting 1
hour) of cognitive-behavioural group treatment for
chronic insomnia. Each group consisted of 5 patients. The
purpose of this treatment was to help the patients to iden-
tify and modify their dysfunctional insomnia-related
thoughts, beliefs, and behaviour, and to break the recur-
ring cycle of anticipatory anxiety. The major components
of CBT were:
(a) sleep education and cognitive restructuring concern-
ing sleep (i.e., recognizing, challenging, and changing dis-







Age [years] 45.23 (s.d. 14.53) 42.27 (s.d. 13.54) p = 0.58a
Gender [female : male] 9 : 4 10 : 5 p = 0.60b
Duration of disorder [insomnia length in months] 48 (IQR 17–204)* 60 (IQR 24–147)* p = 0.62c
Insomnia Severity Index [ISI] 16.54 (s.d. 4.19) 18.67 (s.d. 4.93) p = 0.23a
Epworth Sleepiness Scale [ESS] 12.15 (s.d. 5.83) 11.40 (s.d. 4.88) p = 0.71a
Beck Depression Inventory [BDI] 7.0 (IQR 2–11)* 6.5 (IQR 2.0–9.25)* p = 0.56c
Beck Anxiety Inventory [BAI] 10.31 (s.d. 6.21) 9.87 (s.d. 6.79) p = 0.86a
Hamilton Rating Scale for Depression [HAMD] 7.85 (s.d. 3.36) 5.80 (s.d. 3.38) p = 0.12a
modified Clinical Global Impression Severity [mCGI-S] 10 (IQR 9–11)* 8 (IQR 7–10)* p = 0.18c
Total sleep time TST [min] 344.69 (s.d. 58.14) 292.63 (s.d. 143.06) p = 0.23a
Sleep latency SL [min] 26.0 (IQR 7.15–47.45)* 27.2 (IQR 12.63–45.94)* p = 0.72c
Sleep efficiency SE [%] 75.5 (IQR 63.5–82.0)* 72.0 (IQR 64.0–81.0)* p = 0.86c
Wake after sleep onset WASO [min] 72.42 (s.d. 55.84) 87.37 (s.d. 58.72) p = 0.50a
Stage 1 [min] 36.50 (s.d. 19.74) 31.90 (s.d. 24.50) p = 0.59a
Stage 2 [min] 153.96 (s.d. 82.50) 154.37 (s.d. 40.50) p = 0.98a
Stage 3+4 [min] 105.40 (s.d. 51.00) 120.74 (s.d. 44.50) p = 0.04a
REM [min] 55.90 (s.d. 45.00) 76.77 (s.d. 39.00) p = 0.04a
* Data are presented as median (interquartile range) due to non-normal data distribution. Characters in bold indicate significance (p < 0.05).
a – One-way ANOVA; b – Fischer Exact Test; c – Mann-Whitney U Test;
IQR – interquartile range; s.d. – standard deviation; N.S. – non significantPage 3 of 7
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requirements, attributions, effects of sleep loss, and sub-
jective perception of amount of sleep obtained),
(b) information on sleep hygiene (i.e., reducing alcohol,
caffeine, and nicotine use; increasing daytime exercise but
not within 4 hours of bedtime; establishing a regular
wind-down period prior to bedtime; avoiding stimulating
mental and physical activities before bedtime; maintain-
ing a quiet, cool, and dark bedroom; etc.),
(c) behaviour therapy, sleep restriction, and stimulus con-
trol (employing a regular arising time; limiting time in
bed to 1.5 hours beyond the average sleep length, as cal-
culated from weekly sleep diaries, to improve sleep effi-
ciency; using the bedroom for sleep or relaxing activities
only; going to bed only when drowsy; and, if not asleep
within 20 to 30 minutes, opening eyes and engaging in
relaxing activity in bed or another room with no attempt
to sleep until drowsy again, with repetition as necessary),
(d) cognitive therapy, work with autonomic negative
though, work with behaviour, emotion, thoughts, physi-
cal reaction and cognitive restructuring (i.e., recognizing,
challenging, and changing distorted negative cognitive
appraisals concerning daily stressors), and
(e) progressive relaxation (a set of integrated physiologic
changes that are consistent with reductions in sympa-
thetic nervous system activity and that are elicited when
an individual engages in a repetitive mental activity –
muscular relaxation and breath focusing, while passively
ignoring distracting thoughts) [20-22].
Sessions were supplemented with educational and direc-
tive reading materials.
Statistical analysis
To compare the pre- and post-treatment variables, the
paired t-test and ANOVA were applied. For data with non-
normal statistical distribution, nonparametric statistical
tests were used to perform within group (Wilcoxon Sign
Rank Test) and between group (Mann-Whitney U Test and
Fisher Exact Test) analyses (statistical software SPSS
v.12.0). The intention was to examine the changes in sleep
variables achieved by therapy. The influence of hypnotics'
discontinuation was investigated, as a possible factor
regarding various sleep parameters by General Linear
Model completed by post-hoc t-test. Differences between
the pre- and post-treatment values were used as input data
for investigating changes during therapy.
Results
Effects of hypnotic abuse on subjective and objective sleep 
variables
At the beginning of the treatment period, both subgroups
of patients were examined using traditional whole-night
sleep polysomnography. In this part of the study, pre-
treatment data obtained from the hypnotic abusing
patients were compared to data obtained from the non-
abusing patients. The mean values of the sleep indicators
(subjective and objective clinical scales, sleep continuity,
and sleep architecture) for both subgroups are displayed
separately in Table 1. While sleep was clearly disturbed in
all patients, there were no significant differences in base-
line subjective and objective clinical scales values between
hypnotic abusers and non-abusing patients. Among poly-
somnographic parameters the proportion of slow wave
sleep of stages 3 and 4 was relatively increased in those
patients abusing third-generation hypnotics. Similarly,
the proportion of REM sleep was higher in hypnotic-abus-
ing patients than in non-abusing ones.
Effects of CBT on clinical scales and sleep variables
The differences between pre- and post-treatment sleep var-
iables served as indicators of treatment outcome. In this
part of the study, the therapeutic result was evaluated in
all 28 patients, with both subgroups combined. The base-
line data obtained by subjective clinical scales and polys-
omnography before therapy are displayed in the second
column of Table 2. The table shows the means/medians
and standard deviations/interquartile ranges as registered
in the entire group, including both hypnotic-abusing and
non-abusing patients. Sleep disturbance was reflected, for
example, in the measure of sleep efficiency, with a mean
value of 77.58% (± 19.28). The other polygraphic varia-
bles, obtained before therapy, are also revealed in the sec-
ond column ("pre-treatment"). The mean/median values
of the same clinical scales and sleep variables, obtained
after CBT are displayed in the third column ("post-treat-
ment"). A statistical comparison between the pre- and
post-treatment data reveals a significant improvement in
almost all sleep parameters after therapy. The exceptions
was the amount of sleeping time spent in sleep 2 and sleep
1 stages, which were somewhat lower after CBT, but the
difference was not statistically significant.
Effects of hypnotic discontinuation on sleep variables
The differences between pre- and post-treatment sleep var-
iables also served as indicators of treatment outcome. The
intention of this part of the study was to compare treat-
ment outcomes achieved in the hypnotics-abusing
patients to outcomes achieved in non-abusing patients.
Thus, statistical analysis should evaluate whether the
treatment outcome (i.e., difference between post- and pre-
treatment variables) was influenced by past hypnotic
abuse and withdrawal of hypnotics during the treatmentPage 4 of 7
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subgroups, and possible additional effects of the with-
drawal of hypnotic were investigated. Sleep efficiency (SE)
and wake after sleep onset (WASO) improved signifi-
cantly after the discontinuation of third-generation hyp-
notics (Table 3).
Effects of discontinuation of hypnotics on clinical variables
The above described results were obtained by means of
polysomnography. It was of interest to determine whether
changes in polysomnographic variables were paralleled
by changes in clinical variables. Parallel changes would
suggest a possible relationship between improvement in
sleep variables and improvement in clinical scores. A par-
allel relationship was found between diminished anxiety
(Beck Anxiety Inventory) and a decrease in WASO. A
detailed analysis of this result, as displayed in Table 4,
revealed that the decrease in WASO was actually influ-
enced by a combination of two factors: decrease of anxi-
ety, and discontinuation of hypnotics.
Table 2: Comparison of clinical symptom scales and sleep parameters before and after CBT, n = 28.
Pre-treatment Post-treatment Significance
Insomnia Severity Index [ISI] 17.68 (s.d. 4.49) 10.89 (s.d. 5.40) p < 0.001a
Epworth Sleepiness Scale [ESS] 11.75 (s.d. 5.25) 8.64 (s.d. 5.07) p = 0.03a
Beck Depression Inventory [BDI] 7.0 (IQR 2.0–10.0)* 2.0 (IQR 0–6.0)* p < 0.001b
Beck Anxiety Inventory [BAI] 10.07 (s.d. 6.41) 5.39 (s.d. 4.43) p = 0.002a
Hamilton Rating Scale for Depression [HAMD] 6.5 (IQR 3.0–10.5)* 1.0 (IQR 0–1.5)* p < 0.001b
modified Clinical Global Impression [mCGI]
(mCGI-Severity for pre-treatment and mCGI-Impression for post-treatment conditions)
9.0 (IQR 8.0–10.0)* 4.0 (IQR 2.0–4.5)* p < 0.001b
Total sleep time TST [min] 361.80 (s.d.113.20) 454.12 (s.d.59.37) p = 0.01a
Sleep latency SL [min] 26.0 (IQR 11.98–46.10)* 7.25 (IQR 3.83–13.0)* p = 0.004b
Sleep efficiency SE [%] 77.58 (s.d. 19.28) 89.60 (s.d. 8.43) p = 0.004a
Wake after sleep onset WASO [min] 80.42 (s.d. 56.85) 48.27 (s.d. 37.17) p = 0.02a
Stage 1 [min] 28.5 (IQR 22.0–41.75)* 22.75 (IQR 16.5–37.0)* p = 0.29b
Stage 2 [min] 154.48 (s.d. 51.43) 149.12 (s.d. 55.72) p = 0.72a
Stage 3+4 [min] 112.52 (s.d. 80.62) 175.09 (s.d. 94.09) p = 0.01a
REM [min] 65.59 (s.d. 43.49) 107.91 (s.d. 49.12) p = 0.001a
In most cases data are expressed as the mean (standard deviation). Characters in bold indicate significance (p < 0.05).
* Data are presented as median (interquartile range) due to non-normal data distribution
a – Paired-Samples T test; b – Wilcoxon Sign Rank Test;
IQR – interquartile range; s.d. – standard deviation; N.S. – non significant






Insomnia Severity Index [ISI] -5.7 (s.d. 4.93) -6.9 (s.d. 3.97) p = 0.48a
Epworth Sleepiness Scale [ESS] -2.00 (IQR -4.0 – 0)* -1.5 (IQR -2.5 – 0.25)* p = 0.43b
Beck Depression Inventory [BDI] -4.33 (s.d. 4.53) -3.50 (s.d. 3.94) p = 0.61a
Beck Anxiety Inventory [BAI] -5.00 (s.d. 4.60) -4.71 (s.d. 5.77) p = 0.88a
Hamilton Rating Scale for Depression [HAMD] -4.0 (IQR -9.0 – -2.0)* -3.50 (IQR -9.75 – -2.75)* p = 0.98b
modified Clinical Global Impression Improvement [mCGI-I] 4.0 (IQR 3.0–5.0)* 3.0 (IQR 2.0–4.0)* p = 0.16b
Total sleep time TST [min] 84.60 (s.d. 101.36) 83.28 (s.d. 137.99) p = 0.98a
Sleep latency SL [min] -12.25 (IQR -25.0 – 2.0)* -17.00 (IQR -31.68 – -5.75)* p = 0.48b
Sleep efficiency SE (%) 6.16 (s.d. 6.12) 19.95 (s.d. 25.0) p = 0.02a
Wake after sleep onset WASO (min) -25.81 (s.d. 28.69) -36.86 (s.d. 71.94) p = 0.003a
Stage 1 [min] -4.20 (s.d. 21.17) -2.64 (s.d. 26.11) p = 0.87a
Stage 2 [min] -3.43 (s.d. 56.79) -4.88 (s.d. 49.25) p = 0.94a
Stage 3+4 [min] 68.34 (s.d. 98.00) 61.90 (s.d. 86.46) p = 0.86a
REM [min] 45.88 (s.d. 69.41) 36.23 (s.d. 52.13) p = 0.68a
In most cases change is expressed as the mean difference (standard deviation) between values obtained after and before therapy. Characters in bold 
indicate significance (p < 0.05).
* Data are presented as median (interquartile range) due to non-normal data distribution
a – One-way ANOVA; b – Mann-Whitney U Test;
IQR – interquartile range; s.d. – standard deviation; N.S. – non significantPage 5 of 7
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Many patients suffering from chronic insomnia partici-
pate in long-term daily use of hypnotics. Those who are
inadequately treated have a tendency to increase their
daily dose in an effort to combat their continuing insom-
nia. Such patients are clearly at risk for hypnotics abuse
and dependence. Application of CBT for insomnia is the
best way to avoid such developments and to ensure
proper therapy in these patients. Therapists are less cer-
tain, however, what to do regarding the ongoing hypnotic
regimen during CBT. Discontinuation of hypnotic admin-
istration is not always possible, because both the patient
and the therapist may be concerned about worsening
insomnia. There is a fear that abrupt withdrawal of hyp-
notics could result in worse therapeutic outcomes. How-
ever, practical experience with discontinuation of
hypnotics does not justify this concern. There are reports
on long-term outcomes of discontinuing hypnotics, par-
ticularly benzodiazepines [7,10].
On the other hand, experience concerning other types of
hypnotics is rather limited. Therefore, a study aiming to
contribute further observations regarding therapeutic out-
comes after discontinuing hypnotics has been initiated. In
contrast to previous studies, this study was focused on
third-generation hypnotics [8,10,23]. Although the risks
of abuse and dependence seem to be lower in third-gener-
ation hypnotics than in other hypnotic drug classes, with-
drawal of third-generation hypnotics is also often
desirable. The study should elucidate which changes in
sleep characteristics are caused by a long-term intake of
the drugs and, in particular, what the therapeutic outcome
would be after their discontinuation.
In this study, two subgroups of patients, with and without
a history of hypnotic abuse, were examined. To shed light
on the effect of a long-term hypnotics regimen, pre-treat-
ment sleep indicators were considered. In hypnotics-abus-
ing patients a relative increase in sleep stage 3, sleep stage
4, and REM sleep could be demonstrated in comparison
with the hypnotic non-abusing subgroup. Both subgroups
of patients were then treated with CBT while the long-
term hypnotic regimen was gradually discontinued. After-
wards, the therapeutic outcomes were evaluated, using the
differences between pre- and post-treatment sleep varia-
bles as indicators. Sleep was significantly improved in
both subgroups after CBT. The only exception was the
proportion of sleep stages 1 and 2, in which statistical sig-
nificance could not be confirmed. As a next step, the pos-
sible effects of discontinuing hypnotics were investigated.
Statistical analysis revealed an additional improvement of
sleep efficiency and WASO in the abusing group after ther-
apy.
One possible objection is that several factors influencing
sleep in parallel could not be studied separately because it
was necessary to respect the patients' interests to obtain
efficient therapy by means of CBT [9]. These drawbacks
are certainly compensated for by using an objective
method to follow the quality of sleep as well as changes in
sleep quality. Many studies are based on the subjective
reports of patients, even though, as shown in our previous
study, subjective data may be less reliable than expected
[24]. Researchers are well aware of the fact that evaluation
of subjective variables is to be expected in a study of this
type. However, considering that the unreliability of sub-
jective sleep data variables has been previously demon-
strated, it would certainly be improper to continue to use
them in future studies of this type. To avoid any confusion
due to the use of insufficient data, it was decided to base
findings and conclusions on objective variables obtained
by means of polysomnographic examination.
Several questions remain unanswered, and a new study,
conducted independently and with a more extensive
study population, will be necessary to confirm these find-
ings. However, enrolment of a large patient population,
particularly of patients without any previous medication
history, is a difficult task. Of course, results for which the
statistical significance was confirmed can hardly be
Table 4: Effect of hypnotic discontinuation and reduced anxiety as possible factors reducing wake after sleep onset. Dependent 
variable: WASO (wake after sleep onset).
Source Sum of Squares df Mean Square F-value Significance
Corrected Model 25643.428 6 4273.905 2.425 p = 0.04
Intercept 6782.891 1 6782.891 3.848 p = 0.06
Hypnotic withdrawn * BAI 9464.062 1 9464.062 5.369 p = 0.03
Hypnotics withdrawn 19912.822 1 19912.822 11.297 p = 0.003
BAI 8910.463 1 8910.463 5.055 p = 0.04
Error 37015.599 21 1762.648
Total 91619.750 28
Corrected Total 62659.027 27
df – degree of freedom; BAI – Beck Anxiety Inventory;
Characters in bold indicate significance (p < 0.05).Page 6 of 7
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trary, it is only plausible to expect more pronounced
changes and higher significance with a larger patient pop-
ulation. Another possible objection concerns therapeutic
outcomes. This study does not provide information
regarding the durability of therapeutic effects, and a fol-
low-up study will therefore be necessary. Furthermore,
considering the practical consequences of the study, it
should be emphasized that these findings concern third-
generation hypnotics only. Possible interference with
other medications was avoided in this study. Thus, the
experience gained from this study is not necessarily appli-
cable to all types of patients or hypnotic medications.
Conclusion
In summary, the present findings extend those from pre-
vious studies in documenting the efficacy of CBT in treat-
ing chronic primary insomnia. Summarizing all the
positive and negative points of our study, it seems indis-
putable that the discontinuation of long-term daily hyp-
notic regimens can be done without any hesitation in
patients with primary insomnia. The results of the study
suggest that withdrawal of third-generation hypnotics can
improve rather than worsen the results of CBT in treating
chronic insomnia.
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